Virtus ETF Advisers LLC I Mab Transaction History

Virtus ETF Advisers LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$3.08 - $7.39 $31,197 - $74,853	-10,129 Reduced 27.77%	26,347 $91,000
Q4 2022 Feb 14, 2023	BUY	$3.22 - $4.86 $80,322 - $121,232	24,945 Added 216.33%	36,476 $152,000
Q3 2022 Nov 14, 2022	BUY	$4.01 - $12.34 $340 - $1,048	85 Added 0.74%	11,531 $46,000
Q2 2022 Aug 12, 2022	BUY	$8.27 - $18.43 $68,723 - $153,153	8,310 Added 264.99%	11,446 $129,000
Q1 2022 May 16, 2022	SELL	$12.54 - $46.93 $2,370 - $8,869	-189 Reduced 5.68%	3,136 $51,000
Q4 2021 Feb 14, 2022	BUY	$45.28 - $74.5 $18,112 - $29,800	400 Added 13.68%	3,325 $158,000
Q3 2021 Nov 15, 2021	SELL	$57.18 - $84.43 $9,205 - $13,593	-161 Reduced 5.22%	2,925 $212,000
Q2 2021 Aug 10, 2021	SELL	$47.86 - $83.95 $228,483 - $400,777	-4,774 Reduced 60.74%	3,086 $259,000
Q1 2021 May 17, 2021	BUY	$44.38 - $63.97 $5,991 - $8,635	135 Added 1.75%	7,860 $381,000
Q4 2020 Feb 12, 2021	BUY	$32.94 - $47.15 $254,461 - $364,233	7,725 New	7,725 $364,000

16.4M

1.9K

Ticker IMAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,098,800
Market Cap $108M
Description
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinica...

Get notified when there are updates to the investment portfolio of Virtus ETF Advisers LLC, based on Form 13F filings with the SEC.

Stay updated on Virtus ETF Advisers LLC with notifications on news.